Advertisement

Reactions Weekly

, Volume 1747, Issue 1, pp 19–19 | Cite as

Alemtuzumab/rituximab

Various toxicities: 6 case reports
Case report
  • 32 Downloads

Reference

  1. Alcala C, et al. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology 266: 726-734, No. 3, Mar 2019. Available from: URL: http://doi.org/10.1007/s00415-019-09195-2 - SpainCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations